<DOC>
	<DOCNO>NCT02641990</DOCNO>
	<brief_summary>A Phase 1 , randomize , double-blind , placebo-controlled , crossover study assess effect ITCA 650 pharmacokinetics ( PK ) daily administration Levora® ( ethinyl estradiol 0.3 mg ( EE ) levonorgestrel 0.15 mg ( LNG ) healthy premenopausal female subject .</brief_summary>
	<brief_title>Study Effect ITCA 650 PK/PD Oral Contraceptive Healthy Female Subjects</brief_title>
	<detailed_description />
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Women childbearing potential . Use combination oral contraceptive ≥3 month immediately prior screening . Willing use additional adequate method contraception study 1 additional menstrual cycle follow endofstudy ( EOS ) visit . Adequate method contraception woman child bear potential ( WOCBP ) include : mechanical product ( ie , intrauterine device [ IUD ] —copper IUD ) ; barrier method ( eg , diaphragm , condom , cervical cap ) spermicide . Body mass index ( BMI ) ≥19 ≤32 kg per meter square . Weight ≥50 ≤100 kg . Nonsmoker exsmoker &gt; 6 month prior screen ( stop use nicotine product ≥2 week prior screen ) . History type 1 type 2 diabetes . Received implanted contraceptive within 6 month prior screen inject contraceptive within 12 month prior screen . History evidence , within last 6 month prior Screening Visit , myocardial infarction , coronary revascularization ( coronary artery bypass graft percutaneous coronary intervention ) , unstable angina , cerebrovascular accident stroke . History uncontrolled hypertension . History evidence acute chronic pancreatitis . History liver disease . History medullary thyroid cancer personal family history multiple endocrine neoplasia type 2 . Poor thyroid , liver , renal function . Weight loss surgery require weight loss medication . History malignancy ( include basal squamous cell carcinoma skin past 5 year ) . ( Subjects disease free 5 year may include . ) Estrogendependent growth ; undiagnosed vaginal bleeding . History active alcohol substance abuse . Regular daily consumption 12 g alcohol form . Excessive xanthine consumption ( 5 cup coffee equivalent per day ) . Treatment medication affect GI motility . Any condition would affect drug transit time absorption ( eg , gastrointestinal bypass surgery , partial total gastrectomy , small bowel resection , chronic diarrhea , vagotomy , chronic gastroesophageal reflux disease , malabsorption , colostomy , Crohn 's disease , ulcerative colitis , celiac sprue ) . History hypersensitivity exenatide . Contraindications warning accord specific label ( ) EE and/or LNG therapy . Women pregnant , lactating , plan become pregnant . Any use anticoagulant exception give prophylaxis prior surgical intervention . History positive result screen test hepatitis B and/or hepatitis C and/or human immunodeficiency virus ( HIV ) . Recent surgery plan inpatient surgery , dental procedure , hospitalization study . History migraine age &gt; 35 year focal symptom associate migraine . History thrombophlebitis , thromboembolic disorder , deep vein thrombophlebitis . Fasting triglyceride upper limit normal Screening . Any gastrointestinal complaint within 7 day prior first dosing .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>